Ahn, Myung-Ju; Tsai, Chun-Ming; Hsia, Te-Chun; Wright, Elaine; Chang, John Wen-Cheng; Kim, Heung Tae; Kim, Joo-Hang; Kang, Jin Hyoung; Kim, Sang-We; Bae, Eun-Jin; Kang, Mijeong; Lister, Johanna; Walzer, Stefan
Asia-Pacific journal of clinical oncology
2011Jun ; 7 Suppl 2 ( 6 ) :22-33.
PMID : 21585705
ÀúÀÚ »ó¼¼Á¤º¸
Ahn, Myung-Ju -
Tsai, Chun-Ming -
Hsia, Te-Chun -
Wright, Elaine -
Chang, John Wen-Cheng -
Kim, Heung Tae -
Kim, Joo-Hang -
Kang, Jin Hyoung -
Kim, Sang-We -
Bae, Eun-Jin -
Kang, Mijeong -
Lister, Johanna -
Walzer, Stefan -
ABSTRACT
AIMS: The aim of this analysis is to investigate the mean incremental costs and life expectancy associated with two first-line treatments for advanced non-squamous non-small cell lung cancer (NSCLC) in Korea and Taiwan; bevacizumab plus cisplatin and gemcitabine (BevCG) and cisplatin plus pemetrexed (CP).
METHODS: A health economic (area under curve) model with three health states was developed to assess health outcomes (life-years gained [LYG]), direct costs, and incremental cost-effectiveness ratio (ICER). Progression-free survival (PFS) and overall survival (OS) were derived from randomized clinical trials and used in an indirect comparison in order to estimate their cost effectiveness. A life-time horizon was used. Costs and outcomes were discounted yearly by 5% in Korea and by 3% in Taiwan.
RESULTS: The incremental LYG for the BevCG patients compared with patients treated with CP were 1.10 (13.2 months) in Korea and 1.19 (14.3 months) in Taiwan. The incremental costs were 37,439,968 ($ 33,322) in Korea and NT$ 1,910,615 ($ 64,541) in Taiwan. The incremental cost-effectiveness ratio was 34,064,835 ($ 30,318) in Korea and NT$ 1,607,960 ($ 54,317) in Taiwan. The inputs tested in one-way sensitivity analyses had very little impact on the overall cost effectiveness. CONCLUSION: This analysis shows that BevCG is more costly but is also associated with additional life-years in Korea and Taiwan. The ICER per LYG suggests that BevCG is a cost-effective therapy when compared to CP for patients with advanced NSCLC in Korea and Taiwan. CI - ??2011 Blackwell Publishing Asia Pty Ltd.
Adult; Aged; Antibodies, Monoclonal/administration & dosage/*economics/*therapeutic use; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols/*economics/*therapeutic use; Carcinoma, Non-Small-Cell Lung/*drug therapy/economics; Cisplatin/administration & dosage; Cost-Benefit Analysis; Disease-Free Survival; Female; Glutamates/administration & dosage; Guanine/administration & dosage/analogs & derivatives; Humans; Korea; Lung Neoplasms/*drug therapy/economics; Male; Middle Aged; Survival Analysis; Taiwan
MESH
Adult, Aged, Antibodies, Monoclonal/administration & dosage/*economics/*therapeutic use, Antibodies, Monoclonal, Humanized, Antineoplastic Combined Chemotherapy Protocols/*economics/*therapeutic use, Bevacizumab, Carcinoma, Non-Small-Cell Lung/*drug therapy/economics, Cisplatin/administration & dosage, Cost-Benefit Analysis, Disease-Free Survival, Female, Glutamates/administration & dosage, Guanine/administration & dosage/analogs & derivatives, Humans, Korea, Lung Neoplasms/*drug therapy/economics, Male, Middle Aged, Pemetrexed, Survival Analysis, Taiwan
¸µÅ©